Expect Integrase Inhibitors to Gain an Edge in Treating HIV

October 2018

Updated guidelines will lead to a shift in preferred antiretroviral meds for treating HIV in adults.

Expect more patients to start regimens with integrase inhibitors...especially bictegravir (Biktarvy) or dolutegravir (Tivicay, etc).

That's because integrase inhibitors are often better tolerated than protease inhibitors, such as Prezista...or NON-nucleoside reverse transcriptase inhibitors (NNRTIs), such as Sustiva.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Influenza Sort Out Influenza Vaccine Options for 2018-19
Cardiology Address Depression in Post-MI Patients
Pregnancy Use FDA's Updated System to Decipher Med Safety in Pregnancy
Dermatology Help Get to the Bottom of Diaper Rash
Hematology & Oncology Watch for Autoimmune-Like Effects From Cancer Immunotherapy
Pharmacogenetics Don't Recommend Pharmacogenetic Testing for Most Patients
Endometriosis Consider Orilissa for Some Women With Endometriosis
Natural Medicines Focus on Safety if Patients Use Essential Oils
Generics Prepare for Generic Tadalafil and Vardenafil
HIV & AIDS Expect Integrase Inhibitors to Gain an Edge in Treating HIV
Epinephrine Be Ready for Questions About EpiPen Shortages and Generics
Antipsychotics Compare Aristada Initio and Perseris to Other Injectable Antipsychotics
Medicare Be Ready for Questions About 2019 Medicare Part D Changes

Expect Integrase Inhibitors to Gain an Edge in Treating HIV

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents